---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-021039"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-07-25T23:59:59+00:00"
generated_at: "2026-05-18T01:22:53.293267+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Calidi eliminates President role; approves 1-for-12 reverse stock split effective Aug 5, 2025

## Summary
- Calidi eliminated the President, Medical & Scientific Affairs position held by Dr. Boris Minev, effective July 29, 2025; CMO Dr. Guy Travis Clifton assumes duties.
- Reverse stock split at 1-for-12 ratio; shares expected to begin trading on split-adjusted basis on NYSE American at market open August 5, 2025.
- Stockholders approved the reverse split on July 9, 2025; Board approved ratio on July 11, 2025; new CUSIP is 320703 408.
- Fractional shares will be rounded up to the nearest whole share; no action required for book-entry or street name holders.

## SEC filing metadata
- accession: 0001641172-25-021039
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000164117225021039/0001641172-25-021039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000164117225021039/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-021039
- JSON: https://secwatch.observer/filing/0001641172-25-021039.json
- Plain text: https://secwatch.observer/filing/0001641172-25-021039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.